First-Line Treatment of Stage I/II DLBCL

Preliminary findings from a phase 2 trial show clinical activity with MB-105 in patients with relapsed/refractory T-cell lymphoma.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.